Redhill Biopharma
RDHL
#10477
Rank
HK$30.82 M
Marketcap
HK$9.26
Share price
-0.83%
Change (1 day)
-84.07%
Change (1 year)

Revenue for Redhill Biopharma (RDHL)

Revenue in 2022: HK$0.48 Billion

According to Redhill Biopharma's latest financial reports the company's current revenue (TTM ) is HK$0.27 Billion. In 2022 the company made a revenue of HK$0.48 Billion a decrease over the revenue in the year 2021 that were of HK$0.66 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Redhill Biopharma from 2012 to 2022

Annual revenue

Year Revenue Change
2022HK$0.48 B-27.79%
2021HK$0.66 B34.03%
2020HK$0.49 B918.31%
2019HK$48.99 M-25.16%
2018HK$65.46 M109.11%
2017HK$31.3 M3897.2%
2016HK$0.78 M3268.33%
2015HK$0.02 M-99.96%
2014HK$54.4 M58365.98%
2013HK$0.09 M-24.97%
2012HK$0.12 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Sanofi
SNY
HK$369.74 B 132,855.88%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
HK$499.75 B 179,603.46%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
HK$329.50 B 118,385.88%๐Ÿ‡ฌ๐Ÿ‡ง UK
Taro Pharmaceutical
TARO
HK$4.75 B 1,608.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Teva Pharmaceutical Industries
TEVA
HK$130.51 B 46,832.44%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel